Loading...

Catabasis Pharmaceuticals

DB:209A
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
209A
DB
$93M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Catabasis Pharmaceuticals has significant price volatility in the past 3 months.
209A Share Price and Events
7 Day Returns
-10.6%
DB:209A
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-47.4%
DB:209A
-10.2%
DE Biotechs
-6%
DE Market
209A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Catabasis Pharmaceuticals (209A) -10.6% 9.9% 21.1% -47.4% - -
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • 209A underperformed the Biotechs industry which returned -10.2% over the past year.
  • 209A underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
209A
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Catabasis Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Catabasis Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €7.264.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Catabasis Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Catabasis Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:209A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-5.12
NasdaqGM:CATB Share Price ** NasdaqGM (2019-04-18) in USD $8.1
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Catabasis Pharmaceuticals.

DB:209A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CATB Share Price ÷ EPS (both in USD)

= 8.1 ÷ -5.12

-1.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catabasis Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Catabasis Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Catabasis Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:209A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.58x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
45.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Catabasis Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Catabasis Pharmaceuticals's assets?
Raw Data
DB:209A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.89
NasdaqGM:CATB Share Price * NasdaqGM (2019-04-18) in USD $8.1
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
DB:209A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CATB Share Price ÷ Book Value per Share (both in USD)

= 8.1 ÷ 4.89

1.66x

* Primary Listing of Catabasis Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Catabasis Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Catabasis Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Catabasis Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Catabasis Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
45.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Catabasis Pharmaceuticals expected to grow at an attractive rate?
  • Catabasis Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Catabasis Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • Catabasis Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:209A Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:209A Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 45.1%
DB:209A Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 66.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:209A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:209A Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 220 83 1
2022-12-31 110 47 2
2021-12-31 8 -39 2
2020-12-31 0 -29 2
2019-12-31 0 -26 2
DB:209A Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -23 -26
2018-09-30 0 -24 -25
2018-06-30 1 -25 -27
2018-03-31 1 -26 -27
2017-12-31 1 -27 -27
2017-09-30 0 -29 -31
2017-06-30 -29 -32
2017-03-31 -32 -35
2016-12-31 -33 -36
2016-09-30 -34 -37
2016-06-30 -35 -37
2016-03-31 -32 -36

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Catabasis Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Catabasis Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:209A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Catabasis Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:209A Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 5.68 5.68 5.68 1.00
2022-12-31 3.14 6.15 0.12 2.00
2021-12-31 -2.61 -1.76 -4.06 3.00
2020-12-31 -2.35 -2.02 -2.68 3.00
2019-12-31 -2.67 -2.09 -3.43 3.00
DB:209A Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -5.12
2018-09-30 -6.57
2018-06-30 -10.14
2018-03-31 -11.53
2017-12-31 -12.62
2017-09-30 -14.91
2017-06-30 -17.07
2017-03-31 -20.10
2016-12-31 -22.22
2016-09-30 -23.95
2016-06-30 -24.08
2016-03-31 -30.25

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Catabasis Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Catabasis Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Catabasis Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Catabasis Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Catabasis Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Catabasis Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Catabasis Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Catabasis Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Catabasis Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Catabasis Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:209A Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -25.87 9.84 15.63
2018-09-30 0.25 -25.31 9.36 15.74
2018-06-30 0.50 -26.65 9.73 16.56
2018-03-31 0.50 -27.14 10.20 17.27
2017-12-31 0.50 -27.36 10.18 17.41
2017-09-30 0.25 -30.65 10.86 19.70
2017-06-30 -32.05 10.71 20.93
2017-03-31 -34.52 10.82 23.30
2016-12-31 -36.06 11.13 24.43
2016-09-30 -36.89 11.28 24.94
2016-06-30 -36.95 11.27 24.86
2016-03-31 -35.55 10.50 24.01
2015-12-31 -32.63 9.46 22.20
2015-09-30 -29.05 8.31 19.89
2015-06-30 -26.59 7.34 18.63
2015-03-31 -23.92 7.12 16.45
2014-12-31 -21.88 6.73 14.95
2014-09-30 -20.76 6.91 13.80
2013-12-31 -18.12 4.88 13.24
2012-12-31 -15.67 3.98 11.69

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Catabasis Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Catabasis Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Catabasis Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Catabasis Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Catabasis Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Catabasis Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Catabasis Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Catabasis Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Catabasis Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Catabasis Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Catabasis Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Catabasis Pharmaceuticals Company Filings, last reported 3 months ago.

DB:209A Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 34.94 0.00 37.57
2018-09-30 40.52 0.00 43.24
2018-06-30 45.81 0.83 49.93
2018-03-31 12.93 1.66 17.03
2017-12-31 11.79 2.48 16.37
2017-09-30 15.66 3.30 21.71
2017-06-30 21.55 4.11 29.37
2017-03-31 23.96 4.92 31.80
2016-12-31 29.09 5.72 38.53
2016-09-30 36.86 6.52 47.27
2016-06-30 32.81 7.32 42.82
2016-03-31 41.72 8.11 52.58
2015-12-31 50.49 8.89 62.78
2015-09-30 59.54 9.74 72.71
2015-06-30 67.59 9.70 81.55
2015-03-31 13.49 9.66 24.30
2014-12-31 7.20 4.75 14.67
2014-09-30 12.93 4.73 20.65
2013-12-31 27.96 0.00 30.47
2012-12-31 4.29 0.00 5.43
  • Catabasis Pharmaceuticals has no debt.
  • Catabasis Pharmaceuticals has no debt compared to 5 years ago when it was 0.1%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Catabasis Pharmaceuticals has sufficient cash runway for 1.6 years based on current free cash flow.
  • Catabasis Pharmaceuticals has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of -12.4% each year.
X
Financial health checks
We assess Catabasis Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Catabasis Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Catabasis Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Catabasis Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Catabasis Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Catabasis Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Catabasis Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:209A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:209A Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Catabasis Pharmaceuticals has not reported any payouts.
  • Unable to verify if Catabasis Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Catabasis Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Catabasis Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Catabasis Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Catabasis Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Catabasis Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Catabasis Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Catabasis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jill Milne
COMPENSATION $632,619
AGE 50
TENURE AS CEO 10.8 years
CEO Bio

Ms. Jill C. Milne, PhD is the Co-founder of Catabasis Pharmaceuticals, Inc., has been its President and Chief Executive Officer since June 2008 and also served as Principal Financial Officer since April 8, 2016. Ms. Milne co-founded and Senior Director of Biology at Sirtris Pharmaceuticals, Inc. She joined Sirtris from Pfizer Global R&D. As an Associate Director of Biology at Pfizer, she led the biology efforts for a lead discovery group and was head of the Pfizer Drug Pfinder program (www.drugpfinder.com). She has been a Director of Catabasis Pharmaceuticals, Inc since June 2008. Prior to joining Pfizer, she was an ACS Postdoctoral Fellow with Chris Walsh at Harvard Medical School. Ms. Milne received her Ph.D. in Biochemistry from Harvard University and a B.A. in biological chemistry from Wellesley College.

CEO Compensation
  • Jill's compensation has been consistent with company performance over the past year.
  • Jill's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Catabasis Pharmaceuticals management team in years:

3.4
Average Tenure
55
Average Age
  • The tenure for the Catabasis Pharmaceuticals management team is about average.
Management Team

Jill Milne

TITLE
Co-Founder
COMPENSATION
$633K
AGE
50
TENURE
10.8 yrs

Andy Nichols

TITLE
Chief Scientific Officer
COMPENSATION
$433K
AGE
57
TENURE
2.5 yrs

Joanne Donovan

TITLE
Chief Medical Officer & Senior VP of Clinical Development
COMPENSATION
$476K
AGE
61
TENURE
7.8 yrs

Noah Clauser

TITLE
VP of Finance & Controller
TENURE
1.7 yrs

Deirdre Cunnane

TITLE
Chief Legal Officer & Treasurer
AGE
53
TENURE
3.4 yrs
Board of Directors Tenure

Average tenure and age of the Catabasis Pharmaceuticals board of directors in years:

3.2
Average Tenure
60
Average Age
  • The tenure for the Catabasis Pharmaceuticals board of directors is about average.
Board of Directors

Ken Bate

TITLE
Chairman of the Board
COMPENSATION
$83K
AGE
68
TENURE
3.2 yrs

Jill Milne

TITLE
Co-Founder
COMPENSATION
$633K
AGE
50
TENURE
10.8 yrs

Burt Adelman

TITLE
Independent Director
COMPENSATION
$51K
AGE
66
TENURE
3 yrs

Mike Kishbauch

TITLE
Independent Director
COMPENSATION
$51K
AGE
69
TENURE
3 yrs

Gregg Lapointe

TITLE
Director
AGE
59
TENURE
0.3 yrs

Mike Jirousek

TITLE
Member of Scientific Advisory Board
COMPENSATION
$701K
AGE
59
TENURE
3.5 yrs

Eric Brass

TITLE
Member of Scientific Advisory Board

Roger Ulrich

TITLE
Member of Scientific Advisory Board

Jean George

TITLE
Director
COMPENSATION
$46K
AGE
60
TENURE
5.5 yrs

Jay Horton

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Catabasis Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Catabasis Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company’s lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) and malfunctioning of CF transmembrane conductance regulator, as well as for the clearance of pathogens, such as P. aeruginosa and B. cenocepacia; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases consisting of Friedreich's ataxia and amyotrophic lateral sclerosis. In addition, the company offers CAT-2000 compounds, which are SMART linker conjugates of nicotinic acid and EPA that are used for the treatment of nonalcoholic steatohepatitis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Details
Name: Catabasis Pharmaceuticals, Inc.
209A
Exchange: DB
Founded: 2008
$82,798,311
11,495,742
Website: http://www.catabasis.com
Address: Catabasis Pharmaceuticals, Inc.
Building 1400E,
Suite B14202,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CATB Common Shares Nasdaq Global Market US USD 25. Jun 2015
DB 209A Common Shares Deutsche Boerse AG DE EUR 25. Jun 2015
Number of employees
Current staff
Staff numbers
24
Catabasis Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 22:01
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/30
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.